Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicentre, Doubleblind, Placebo-controlled RCT to Evaluate Efficacy and Safety With SC Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitised to Grasses and Cupressaceae

NCT04898283 is registered in ClinicalTrials.gov with Inmunotek S.L. as lead sponsor.

NCT NCT04898283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04898283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicentre, Doubleblind, Placebo-controlled RCT to Evaluate Efficacy and Safety With SC Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitised to Grasses and Cupressaceae
Lead sponsor
Inmunotek S.L.
Phase
Phase 3
Overall status
Recruiting
Start date
May 31, 2021
Completion date
October 31, 2026
Enrollment
180 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, allergic, rhinitis, allergic, rhinoconjunctivitis